AZENTA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 51.53 USD | +0.96% |
|
-4.79% | -20.89% |
Financials (USD)
| Sales 2024 * | 663M | Sales 2025 * | 710M | Capitalization | 2.75B |
|---|---|---|---|---|---|
| Net income 2024 * | -124M | Net income 2025 * | -31M | EV / Sales 2024 * | 4.15 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 3.88 x |
| P/E ratio 2024 * |
-20.8
x | P/E ratio 2025 * |
-84.5
x | Employees | 3,400 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 78% |
More Fundamentals
* Assessed data
More news
Latest transcript on Azenta, Inc.
More recommendations
More press releases
| 1 day | +0.96% | ||
| 1 week | -6.24% | ||
| Current month | -2.07% | ||
| 1 month | +2.02% | ||
| 3 months | -12.72% | ||
| 6 months | -20.89% | ||
| Current year | -20.89% |
1 week
50.80
54.40
1 month
50.2457.26
Current year
47.9569.16
1 year
43.4369.16
3 years
36.01124.79
5 years
21.19124.79
10 years
8.33124.79
| Managers | Title | Age | Since |
|---|---|---|---|
Stephen Schwartz
CEO | Chief Executive Officer | 65 | 10-04-04 |
Herman Cueto
DFI | Director of Finance/CFO | 50 | 23-10-15 |
Michael Paulo
CTO | Chief Tech/Sci/R&D Officer | - | 17-06-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Martin Madaus
BRD | Director/Board Member | 64 | Jan. 29 |
Edward Bousa
BRD | Director/Board Member | 65 | Jan. 29 |
Stephen Schwartz
CEO | Chief Executive Officer | 65 | 10-04-04 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.74% | 144 M€ | -2.79% | ||
| 0.90% | 5 M€ | -1.80% | - | |
| 0.38% | 2 M€ | -.--% | ||
| 0.21% | 14 M€ | +10.32% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-02 | 51.53 | +0.96% | 419,712 |
| 24-07-01 | 51.04 | -3.00% | 506,508 |
| 24-06-28 | 52.62 | +1.00% | 969,075 |
| 24-06-27 | 52.1 | -3.70% | 555,870 |
| 24-06-26 | 54.1 | -0.04% | 440,962 |
Delayed Quote Nasdaq, July 02, 2024 at 04:00 pm EDT
More quotes
Azenta, Inc. is a provider of biological and chemical compound sample exploration and management solutions for the life sciences industry. The Companyâs segments include Sample Management Solutions, Multiomics and B Medical Systems. The Sample Management Solutions segment offers end-to-end sample management products and services, including sample and repository services and core products (automated stores, cryogenic systems, automated sample tube, and consumables and instruments). The Multiomics segment provides genomic and other sample analysis services, including gene sequencing and gene synthesis. B Medical Systems segment is focused on the manufacturing and distribution of temperature-controlled storage and transportation solutions in international markets to governments, health institutions, and non-government organizations. It provides products and services through its brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, Barkey, and B Medical Systems.
Calendar
2024-08-05
- Q3 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
51.04
USD
Average target price
62.8
USD
Spread / Average Target
+23.04%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -20.89% | 2.75B | |
| +17.72% | 44.44B | |
| -10.33% | 37.99B | |
| +37.55% | 37.75B | |
| +29.36% | 30.78B | |
| -8.44% | 27.38B | |
| +12.45% | 26.17B | |
| +44.19% | 14.15B | |
| +31.93% | 12.59B | |
| -7.67% | 11.28B |
- Stock Market
- Equities
- AZTA Stock
